Alyeska Investment Group’s Achieve Life Sciences ACHV Stock Holding History

Alyeska Investment Group’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-178,389	Closed	-$562K	–	581
2025 Q3	$562K	Sell	178,389 -3,325,944	-95%	-$9.13M	﹤0.01%	557
2025 Q2	$7.92M	Buy	3,504,333 +3,083,333	+732%	+$8.78M	0.03%	379
2025 Q1	$1.12M	Hold	421,000	–	–	﹤0.01%	432
2024 Q4	$1.48M	Sell	421,000 -50,000	-11%	-$227K	0.01%	477
2024 Q3	$2.23M	Hold	471,000	–	–	0.01%	412
2024 Q2	$2.21M	Hold	471,000	–	–	0.01%	403
2024 Q1	$2.14M	Buy	+471,000	New	+$2.09M	0.01%	372

Other funds holding ACHV

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group's ACHV Position: Q4 2025 in Review

Alyeska Investment Group sold out of Achieve Life Sciences (ACHV) in Q4 2025, closing a stake of 178,389 shares — an estimated $562K sold.

Alyeska Investment Group first reported a position in ACHV in Q1 2024 and held it in 7 quarters. The position peaked at $7.92M in Q2 2025. 77 funds tracked by Wall St. Rank hold ACHV as of Q4 2025.

Alyeska Investment Group reported no remaining Achieve Life Sciences position as of Q4 2025 after selling out during the quarter.
Alyeska Investment Group sold 178,389 Achieve Life Sciences shares in Q4 2025, an estimated $562K.
Alyeska Investment Group first reported a position in Achieve Life Sciences in Q1 2024 and held it in 7 quarters.
Alyeska Investment Group's Achieve Life Sciences position peaked at $7.92M in Q2 2025.
77 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q4 2025.

Based on Alyeska Investment Group's 13F filing for Q4 2025, filed 13 Feb 2026.